AURORA, Ontario, April 24 /CNW/ -- Helix BioPharma Corp. (TSX, FSE:
"HBP") today announced that John Docherty, president and chief operating
officer, will present at the BioFinance 2009 Investor Conference at 3:00 p.m.
EDT on Wednesday, April 29, at The Toronto Marriott in Toronto. Mr. Docherty
will provide an overview of the company's leading technology platforms, DOS47
and Biphasix(TM), and its current product development programs, L-DOS47 and
Topical Interferon Alpha-2b. The slide show portion of the presentation will
be posted on the Company's website, www.helixbiopharma.com, on April 29, 2009.
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company specializing in the
field of cancer therapy. The Company is actively developing innovative
products for the prevention and treatment of cancer based on its proprietary
technologies. Helix's product development initiatives include its Topical
Interferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed
on the TSX under the symbol "HBP".
For further information contact:
Investor & Media Relations
Ian Stone Robert Flamm, Ph.D.
Russo Partners LLC Russo Partners LLC
Tel: (619) 814-3510 Tel: (212) 845-4226
Fax: (619) 955-5318 Email:
This News Release contains certain forward-looking statements regarding
the Company's planned presentation at the BioFinance 2009 Investor Conference
and the Company's research and development initiatives, which statements can
be identified by the use of forward-looking terminology such as "will",
"developing", "April 29", or comparable terminology referring to future events
or results. Forward looking statements are statements about the future and are
inherently uncertain, and Helix's actual results could differ materially from
those anticipated in these forward-looking statements as a result of numerous
factors, including without limitation, the risk that the BioFinance
presentation and the posting of the slide show portion of the presentation are
subject to change or cancellation without notice; uncertainty whether L-DOS47
or Topical Interferon Alpha-2b will be successfully developed as a drug or
otherwise commercialized; the need for additional research and development,
the outcome of which is uncertain; the need for clinical trials, the
occurrence and success of which cannot be assured; product liability and
insurance risks; the risk of technical obsolescence; the need for regulatory
approvals, which may not be obtained in a timely matter or at all;
intellectual property risks; marketing/manufacturing and partnership/strategic
alliance risks; the effect of competition; Helix's need for additional future
capital, which may not be available in a timely manner or at all; as well as a
description of other risks and uncertainties affecting Helix and its business,
as contained in news releases and filings with the Canadian Securities
Regulatory Authorities, any of which could cause actual results to vary
materially from current results or Helix's anticipated future results.
Forward-looking statements are based on the beliefs, assumptions, opinions and
expectations of Helix's management at the time they are made, and Helix does
not assume any obligation, except as required by law, to update any
forward-looking statement should those beliefs, assumptions or expectations,
or other circumstances change.
For further information:
For further information: Investor & Media Relations: Ian Stone, Tel:
+1-619-814-3510, Fax: +1-619-955-5318, or email@example.com,
Robert Flamm, Ph.D., +1-212-845-4226, or firstname.lastname@example.org,
both of Russo Partners LLC for Helix BioPharma Corp. Web Site: